|
Targeted therapy Clinical Trials
2 actively recruiting trials
Also known as: Anlotinib (CHIATAI TIANQING PHARMACEUTICAL GROUP, China), RTK inhibitor
Pipeline
Phase 2: 2
Top Sponsors
- Pengyuan Liu1
- Fudan University1
Indications
- Cancer2
- Advanced Colorectal Carcinoma1
- Immunotherapy1
- Metastatic Castration-resistant Prostate Cancer (CRPC)1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.